Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.National Jewish Health, a respiratory hospital, has signed a co-promotion agreement with Phadia, US, a developer of blood test systems, to build recognition of the important role allergy testing plays in the diagnosis and treatment of asthma and other respiratory diseases.
Subscribe to our email newsletter
Under the agreement, National Jewish Health will help create educational programs, activities and literature to promote to pulmonologists the value of understanding allergy in the diagnosis and management of patients with respiratory diseases. National Jewish will discuss available methodologies for in-office testing for allergies in these patients.
Phadia currently has a product for such testing in the office, ImmunoCAP Rapid, which is currently under review by the FDA. Phadia anticipates FDA clearance by the end of the first quarter of 2009.
David Tinkelman, vice president of health initiatives at National Jewish, said: “National Jewish Health is devoted to combating the uncontrolled asthma epidemic in the US and access in our clinics and regional sites to the latest technology will further accelerate our success. Our expertise will be invaluable in creating educational opportunities for this important part of the assessment of patients with respiratory diseases.”